Home
HelpTest Code MET Methemoglobin and Sulfhemoglobin, Blood
Reporting Name
Methemoglobin and Sulfhemoglobin, BUseful For
Diagnosing methemoglobinemia and sulfhemoglobinemia
Identifying cyanosis due to other causes, such as congenital heart disease
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| METH | Methemoglobin, B | No | Yes |
| SULF | Sulfhemoglobin, B | No | Yes |
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole Blood EDTAShipping Instructions
Specimen must arrive within 72 hours of collection.
Necessary Information
Patient's age is required.
Specimen Required
Container/Tube: Lavender top (EDTA)
Specimen Volume: Full tube
Additional Information: Patient's age is required.
Specimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated | 72 hours |
Reference Values
METHEMOGLOBIN
0-11 months: Not established
≥1 year: 0.0-1.5% of total hemoglobin
SULFHEMOGLOBIN
0-11 months: Not established
≥1 year: 0.0-0.4% of total hemoglobin
Day(s) Performed
Monday through Saturday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83050-Methemoglobin
83060-Sulfhemoglobin
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MET | Methemoglobin and Sulfhemoglobin, B | 98902-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 8268 | Methemoglobin, B | 2614-6 |
| 8272 | Sulfhemoglobin, B | 4685-4 |
Clinical Information
Methemoglobin:
When iron in hemoglobin is oxidized from the normal divalent state to a trivalent state, the resulting brownish pigment is methemoglobin. Methemoglobin cannot combine reversibly with oxygen and is associated with cyanosis.
Methemoglobinemia, with or without sulfhemoglobinemia, is most frequently encountered as a result of administration of medications such as phenacetin, phenazopyridine, sulfonamides, local anesthetics, dapsone, or following ingestion of nitrites or nitrates. Congenital methemoglobinemias are rare. They are due to either:
-Deficiency of methemoglobin reductase (also called cytochrome B5 reductase or diaphorase) in erythrocytes, an autosomal recessive disorder
-One of several intrinsic structural disorders of hemoglobin, called methemoglobin-M; all autosomal dominant in inheritance
Methemoglobinemia responds to treatment with methylene blue or ascorbic acid.
Sulfhemoglobin:
Sulfhemoglobin cannot combine with oxygen. Sulfhemoglobinemia is associated with cyanosis and often accompanies drug-induced methemoglobinemia. Sulfhemoglobinemia can be due to exposure to trinitrotoluene or zinc ethylene bisdithiocarbamate (a fungicide), or by ingestion of therapeutic doses of flutamide.
In contrast to methemoglobinemia, sulfhemoglobinemia persists until the erythrocytes containing it are destroyed. Therefore, the blood level of sulfhemoglobin declines gradually over a period of weeks.
Patients with sulfhemoglobinemia often also have methemoglobinemia. There is no specific treatment for sulfhemoglobinemia. Therapy is directed at reversing the methemoglobinemia if present.
Interpretation
In congenital methemoglobinemia, the methemoglobinemia concentration in blood is about 15% to 20% of total hemoglobin. Such patients are mildly cyanotic and asymptomatic.
In acquired (toxic) methemoglobinemia, the concentration may be much higher. Symptoms may be severe when methemoglobin is greater than 40% of hemoglobin. Very high concentrations (>70%) may be fatal.
Method Description
Methemoglobin:
The normal absorption spectrum of oxyhemoglobin has very little optical density above 600 nm. The absorption spectrum of methemoglobin exhibits a small, characteristic peak at 630 nm. This peak is abolished as methemoglobin is converted to cyanmethemoglobin upon addition of potassium cyanide, and the drop in optical density is proportional to methemoglobin concentration.
Sulfhemoglobin:
The normal absorption spectrum of oxyhemoglobin has very little optical density above 600 nm. However, if certain poorly defined hemoglobin denaturation products are present in a hemolysate, there is a broad elevation of the absorption curve in the range of 600 nm to 620 nm. This sulfhemoglobin plateau is not affected by treatment with cyanide. Sulfhemoglobin is not available, nor can it be prepared, in a pure form for preparation of a sulfhemoglobin standard. In calculating sulfhemoglobin concentration, the factor for sulfhemoglobin quantitation is based on studies of Carrico, et al.(Evelyn KA, Malloy HT. Microdetermination of oxyhemoglobin, methemoglobin, and sulfhemoglobin in a single sample of blood. J Biol Chem. 1938;126:655-662; Carrico RJ, Peisach J, Alben JO. The preparation and some physical properties of sulfhemoglobin. J Analyt Biochem. 1978;253(10):2386-2391; So JCC, Ma ESK. Hemoglobin and hemoglobinopathies. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. Elsevier; 2023:chap 77)
Reject Due To
| Gross hemolysis | Reject |
Method Name
Spectrophotometry (SP)
Forms
If not ordering electronically, complete, print, and send a Benign Hematology Test Request Form (T755) with the specimen.